Candida albicans

Overview

Candida albicans is a polymorphic yeast and opportunistic fungal pathogen that is part of the normal human microbiota but can cause disease when host defenses are impaired or local ecological conditions change. It is a major cause of mucosal candidiasis, including oropharyngeal candidiasis, and can also produce invasive fungal infections in immunocompromised individuals. A key feature of its pathogenicity is its ability to form biofilms and to adapt to host niches, including hypoxic microenvironments, which can contribute to persistence and treatment difficulty.

In biomedical research, C. albicans is frequently used as a target organism for antifungal discovery, biomaterials testing, and host–pathogen interaction studies. Recent work has focused on its susceptibility to natural products, nanoparticles, polymer-based delivery systems, and azole-class antifungals, as well as on immune-recognition pathways involving beta-glucan sensing and lectin receptors such as C-type lectin domain containing 6A and C-type lectin domain containing 7A.

Recent Publications Summary

Recent studies on Candida albicans have focused on overcoming antifungal resistance and improving drug delivery or antimicrobial potency through rationally designed peptides, small molecules, and biomaterial-based formulations. A computer-aided redesign of the human salivary peptide histatin 5 produced the optimized derivative Hst 5-22-RW, which showed stronger binding to the C. albicans membrane receptor Ssa1/2, improved antifungal activity, and superior efficacy against fluconazole-resistant strains; RT-qPCR and transmembrane tracking also indicated enhanced cellular transport in C. albicans 42332364Jun. In a separate resistance-focused approach, 49 synthesized isoxazoline derivatives were screened for synergy with fluconazole, and compound 6ao showed potent activity against azole-resistant C. albicans in vitro and therapeutic efficacy in Galleria mellonella larvae and mice, while also reducing MDR1 expression in a multidrug-resistant clinical isolate when combined with fluconazole 42304548Jun.

Natural products and nanomaterials were also evaluated for activity against C. albicans. Essential oil from fresh leaves of Myrcia spectabilis showed moderate antifungal activity, with particularly strong growth inhibition against C. albicans and enhanced activity when combined with fluconazole 42216857May. Biosynthesized selenium nanoparticles from Olea europaea leaf extract inhibited C. albicans most strongly among the tested microbes, producing a large inhibition zone and showing antibiofilm activity 42143081May. Similarly, chitosan-starch biodegradable hydrogels incorporating copper core-shell nanoparticles significantly inhibited C. albicans at concentrations of at least 150 µg/mL while remaining cytocompatible with human dermal fibroblasts and supporting accelerated wound healing in vivo 41962723Apr.

Drug delivery and antifungal targeting strategies were also explored. Voriconazole-loaded dissolving microneedle systems were developed to improve penetration for deep fungal skin infections, with effective insertion into skin, rapid needle dissolution, and sustained drug release, although the abstract does not specify C. albicans-specific outcomes 41967592Apr. Human Dectin-1- and Dectin-2-targeted DectiSomes were evaluated against diverse pathogenic fungi, including C. albicans, as part of an effort to improve antifungal drug delivery using human receptor orthologs 41910313Mar. In addition, zinc acetate was shown to enhance the self-assembly and drug-loading capacity of oleoyl hyaluronan for imidazole-based antimicrobial agents, including miconazole, suggesting a delivery platform relevant to antifungal therapy 41943310Apr.

What Changes, What Holds

1. Resistance-targeted peptide redesign and azole synergy sharpen the antifungal pipeline rather than changing Candida albicans biology
REINFORCES Hst 5-22-RW and compound 6ao extend the established theme that C. albicans is a tractable target for antifungal discovery and resistance-bypassing strategies. They strengthen the case for membrane-targeted peptides and combination approaches against fluconazole-resistant isolates, but they do not alter the baseline account of C. albicans as a polymorphic opportunistic pathogen with biofilm-associated treatment difficulty. The main implication is practical: better leads for resistant disease, not a new role for the organism. 42332364Jun42304548Jun

2. Natural products, selenium nanoparticles, and copper-containing hydrogels add more delivery and potency options without revising the baseline
REINFORCES These studies fit squarely within the existing picture of C. albicans as a frequent test organism for natural products, nanoparticles, and biomaterial formulations. The added value is incremental: they identify additional antifungal and antibiofilm candidates and suggest wound-compatible materials, but they do not challenge the organism’s known pathogenic features or its established susceptibility-testing use case. Any clinical relevance remains preliminary, and the work mainly broadens the menu of candidate interventions. 42216857May42143081May41962723Apr

3. Targeted delivery platforms expand antifungal engineering, but they do not yet establish a new Candida albicans-specific role
METHOD Voriconazole microneedles, Dectin-targeted DectiSomes, and zinc-assisted hyaluronan assembly mainly change how antifungals are delivered or studied. The baseline already anticipates polymer-based delivery systems and host-recognition-linked targeting, so these reports refine that research direction rather than overturning it. The microneedle work is especially method-focused because the abstract does not specify C. albicans-specific outcomes, while the receptor-targeted and zinc-enabled systems suggest platform development more than organism-level insight. 41967592Apr41910313Mar41943310Apr

Overview update candidates: none.